Emerging research suggest Retatru tide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a promising advancement for weight treatment. Preliminary patient trials have demonstrated considerable losses in visceral tissue, possibly surpassing current obesity treatments. Nevertheless , more